TC Biopharm Adjourns Shareholder Meeting Indefinitely

TC Biopharm (Holdings) ( (TCBPY) ) has issued an update.

On May 22, 2025, TC Biopharm (Holdings) PLC convened a general meeting of shareholders, initially announced on May 6, 2025. However, the meeting was adjourned indefinitely by the chairman, with the time and place to be determined and announced later. This adjournment may impact the company’s decision-making processes and stakeholder engagement, as the outcomes of the meeting remain pending.

The most recent analyst rating on (TCBPY) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on TC Biopharm (Holdings) stock, see the TCBPY Stock Forecast page.

Spark’s Take on TCBPY Stock

According to Spark, TipRanks’ AI Analyst, TCBPY is a Underperform.

TC Biopharm’s overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock’s financial instability and operational inefficiencies are major concerns.

To see Spark’s full report on TCBPY stock, click here.

More about TC Biopharm (Holdings)

TC Biopharm (Holdings) PLC is a company based in Scotland, United Kingdom, operating in the biopharmaceutical industry. The company focuses on developing innovative cell-based products for the treatment of cancer and viral infections.

Average Trading Volume: 198,230

Technical Sentiment Signal: Sell

Current Market Cap: $630.9K

See more insights into TCBPY stock on TipRanks’ Stock Analysis page.